KRYS Krystal Biotech, Inc.
Krystal Biotech, Inc. (KRYS) is expected to report earnings on November 2, 2026, before the market open. The consensus earnings estimate is $1.91 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.6% since its last earnings release on August 3, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Krystal Biotech, Inc.
Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs.
Sector
Healthcare
Industry
Biotechnology